

Acknowledgments

I am extremely grateful to everyone who has helped me during my time in Glasgow. I would especially like to thank Professor Sue Barnett for giving me the opportunity to work in her lab and for all her advice, direction and encouragement. I have genuinely enjoyed working with you and hope to continue doing so sometime in the future. I would also like to thank past and present members of the Glial Biology Lab including Susan, Jen, Rebecca, Peter, Calliope, Stephanie, Ale and Mercedes. You guys are magnificent and have truly made my time in Glasgow. A special thanks to Dr Martin McBride and Dr John McClure for all their technical and statistical support with the microarray study. I would also like to thank Professor Hugh Willison, Professor Chris Linington and Dr Tomoko Iwata for support and feedback throughout my PhD.

I am extremely grateful to my family for their enthusiasm and support throughout my entire life. Thank you to my Mum and Dad for always believing in me. A special thank you goes to my little sisterino, Raya; I cannot thank you enough for all the times you made me laugh about my 'cells'. You were always there when I needed you. A huge thank you to my fiancé, Thomas, for your love, support, patience and for putting up with me! I am eternally grateful to you all and I would have never gotten this far without you.

I dedicate this thesis to my mum – for everything

Table of Contents

Acknowledgments	i
Dedication	ii
Tables of Contents	iii
List of Figures	ix
List of Tables	xiii
List of Abbreviations	xiv
Abstract	xvi
Author's Declaration	xviii

Chapter 1

Introduction	1
1.1 Glial Cells in the Central Nervous System	2
1.1.1 Oligodendrocytes	2
1.1.2 Microglia.	9
1.1.3 Astrocytes.	10
1.2 Functions of Astrocytes in Health and Disease.	13
1.2.1 The Blood Brain Barrier	13
1.2.2 Neurotransmitter Control and Synaptogenesis.	14
1.2.3 Water, Ion and pH Balance.	15
1.2.4 Gap Junctions.	15
1.2.5 Energy and Metabolism	16
1.2.6 Neuronal Support	16
1.2.7 Other Astrocytic Functions	17
1.3 Astrocytes and their Role in Multiple Sclerosis	18
1.3.1 Multiple Sclerosis (MS)	18
1.3.2 The Pathophysiology of MS	18
1.3.3 Astrocytes and Myelination	19
1.3.4 Astrocytes and Models of Demyelination	22
1.4 Astrocytes and their Phenotypes	23
1.4.1 Mild Gliosis (Activated Astrocytes)	24
1.4.2 Factors Secreted by Activated Astrocytes	24
1.4.3 Severe Gliosis (Reactive Astrocytes)	27
1.4.4 The Glial Scar	27

1.4.5	Factors Secreted by Reactive Astrocytes	28
1.4.6	Astrocyte Phenotype and Environment	31
1.5	Conclusions	32
1.6	Aims	34

Chapter 2

Materials and Methods		36
2.1	Tissue Culture	37
2.1.1	Astrocyte Culture	37
2.1.2	Olfactory Ensheathing cells (OECs)	38
2.1.3	Myelinating Cultures	38
2.1.4	Conditioning of E15.5 Spinal Cord Cultures	39
2.2	Western Blotting	40
2.3	Enzyme-Linked Immunoabsorbent Assay (ELISA)	41
2.4	Bromodeoxyuridine Assay	42
2.5	Immunohistochemistry	42
2.5.1	General Immunohistochemistry	42
2.5.2	BrdU Immunohistochemistry	43
2.5.3	External Markers	43
2.5.4	Internal Markers	43
2.6	RNA extraction	43
2.7	cDNA Synthesis	44
2.8	Polymerase Chain Reaction	46
2.8.1	Primer Design	46
2.8.2	PCR Reaction	48
2.8.3	Agarose Gel Preparation	49
2.8.4	Running and Visualising the Gel	49
2.9	Quantitative Real Time PCR (qRT-PCR)	49
2.9.1	Plate Preparation	50
2.9.2	Reaction Conditions	50
2.9.3	Data Quantification	51
2.10	Microarray	52
2.10.1	RNA Integrity	52
2.10.2	RNA Amplification and Biotinylation	52
2.10.3	Direct Hybridisation Assay	56

2.10.4	Analysis of BeadChip Data	57
2.11	Microscopy and Image Analysis	57
2.11.1	Neurite Density	59
2.11.2	Myelin Quantification	59
2.11.3	Quantification of Cell Number	60
2.11.4	Cell Proliferation	61
2.11.5	Neurite Diameter	61
2.11.6	GFAP and Nestin Immunoreactivity	61
2.12	Statistical Analysis	62
Chapter 3		63
Characterisation of the Myelinating Culture System		
3.1	Introduction	64
3.1.1	Background	64
3.1.2	Aims	66
3.2	Results	67
3.2.1	Establishment of the Myelinating Culture System	67
3.2.2	Astrocytes, Microglia, and Oligodendrocytes at Different Maturation Stages	69
3.2.3	Neurite Density Increases and OPC Numbers Fall during the Culture Period	69
3.2.4	Myelination Increases over Time in the Myelinating Culture System	71
3.2.5	Underlying Monolayer of Astrocytes contains O4+ Oligodendrocytes	71
3.2.6	Growth Factors can Promote Myelination	74
3.3	Discussion	76
Chapter 4		
The Effect of Ciliary Neurotrophic Factor on Myelination		
4.1	Introduction	82
4.1.1	Background	82
4.1.2	Aims	84
4.2	Results	84

4.2.1	Expression of O4 in Myelinating Cultures after CNTF Treatment	84
4.2.2	Concentration-Dependent Effect of CNTF	85
4.2.3	CNTF does not have a Promyelinating Effect when Cultures are plated on a Monolayer of OECs	85
4.2.4	CNTF does not Induce Oligodendrocyte Proliferation	88
4.2.5	CNTF and Oligodendrocyte Differentiation	88
4.2.6	CNTF and Microglial Activation	91
4.2.7	Effect of CNTF on Neurite Diameter	93
4.2.8	Effect of CNTF on Astrocyte Reactivity	93
4.2.9	Effect of CNTF Treatment on Astrocytic Expression of Nestin	96
4.3	Discussion	99

Chapter 5

	Understanding the role CNTF and its Receptor	102
5.1	Introduction	103
5.1.1	Background	103
5.1.2	Aims	107
5.2	Results	107
5.2.1	Neutralising Antibodies to CNTF Lead to an Increase in Myelination	107
5.2.2	Increase in Myelination with Neutralising Antibodies is only Observed at 4 µg/ml	108
5.2.3	There is a Slight Reduction in CNTF Concentration after Antibody Treatment	108
5.2.4	CNTF and anti-CNTF May Act via Different Pathways	111
5.2.5	Neutralising Antibodies and Oligodendrocyte Differentiation	111
5.2.6	Antibodies to CNTF do not lead to an Increase in Proliferation	114
5.2.7	Neutralisation of CNTF may lead to a Slight Increase in Microglial Activation	117
5.2.8	LIF and anti-LIF Increase Myelination	117
5.3	Discussion	120

Chapter 6

Changing the Phenotype of the Astrocyte and its

Effect on Myelination	125
6.1 Introduction	126
6.1.1 Background	126
6.1.2 Aims	128
6.2 Results	128
6.2.1 Myelination is Reduced on TnC-Astrocytes	128
6.2.2 Astrocytes on PLL and TnC Show Similar Cellular Characteristics.	128
6.2.3 Astrocytes on PLL Resemble the ‘Activated’ Phenotype	130
6.2.4 TnC-Astrocytes as a Substrate for Myelinating Cultures; Can TnC Directly Influence Oligodendrocyte Differentiation?	132
6.2.5 Expression of TnC is Comparable on PLL-Astrocytes and TnC-Astrocytes	132
6.2.6 Quiescent Astrocyte Phenotype can be Overcome by Activated Astrocyte Conditioned Media or CNTF	136
6.3 Discussion	136

Chapter 7

Identification of Molecules Secreted by Activated and Quiescent Astrocytes

7.1 Introduction	143
7.1.1 Background	143
7.1.2 Aims	144
7.2 Results	144
7.2.1 Schematic of Experimental Design and Analysis of Microarray	144
7.2.2 Gene Expression Changes over time in Untreated and CNTF Treated PLL-Astrocytes	145
7.2.3 Very few genes are changed in Untreated PLL-astrocytes compared to those Treated with CNTF	152
7.2.4 Numerous Genes are identified when TnC-astrocytes were compared to untreated and CNTF-Treated PLL-Astrocytes at 4 hours and 24 hours	155
7.2.5 Validation of CXCL10 by qRT-PCR in TnC-Astrocytes	157

7.2.6	CXCL10 Antibodies Increase Myelination in TnC-Astrocyte Cultures	167
7.2.7	CNTF may Regulate the Expression of CXCL10	168
7.3	Discussion	168

Chapter 8

General Discussion	179	
8.1	Cross-talk Between Astrocytes and Neurons	180
8.2	Mechanisms of Action	181
8.3	Astrocyte Phenotype and Control of Myelination	181
8.4	Astrocyte Heterogeneity	182
8.5	Astrocytes Phenotypes <i>In Vivo</i>	183
8.6	Cytokines and Models of Multiple Sclerosis	184
8.7	Future Experiments	184
8.8	Conclusions of Thesis	186

References	188
-------------------------	-----

Appendix	220
-----------------------	-----

List of Figures

Chapter 1

Figure 1.1	Nodes of Ranvier, Location and Structure	3
Figure 1.2	Summary of Oligodendrocyte Differentiation	7
Figure 1.3	Schematic Representations that Summarise Various Astrocytic Functions in the Healthy CNS	20
Figure 1.4	MS Course and Subtypes	21
Figure 1.5	Summary of Astrocyte Phenotypes and Key Molecules used to Identify them	25
Figure 1.6	The Glial Scar	30
Figure 1.7	Schematic Representation of Astrocytes in Activated and Reactive States	33
Figure 1.8	Summary of How Astrocyte Phenotype can Influence Myelination	35

Chapter 2

Figure 2.1	RNA Integrity	55
Figure 2.2	BeadChip Hybridization Chamber	58
Figure 2.3	Loading Bay of BeadChip	58
Figure 2.4	Measurement of Neurite Density	59
Figure 2.5	Myelin Quantification	60

Chapter 3

Figure 3.1	Methodology of Generating a Myelinating Culture System	68
Figure 3.2	Astrocytes, Microglia, and Oligodendrocytes at Different Maturation Stages	70
Figure 3.3	Neurite Density Increases and OPC Numbers Fall during the Culture Period	72
Figure 3.4	Myelination Increases over Time in the Myelinating Culture System	73

Figure 3.5	Underlying Monolayer of Astrocytes contains O4+ Oligodendrocytes	75
Figure 3.6	Growth Factors can Promote Myelination	77
Figure 3.7	Excess Oligodendrocytes, Ensheathment and Myelination Issues	80

Chapter 4

Figure 4.1	CNTF Addition Increases Expression of the O4 Ligand	86
Figure 4.2	Titration of CNTF Produced Variable Effects on Myelination	87
Figure 4.3	CNTF does not have a Promyelinating Effect when Cultures are plated on a Monolayer of OECs	89
Figure 4.4	CNTF Treatment does not lead to an Increase in OPC Proliferation	90
Figure 4.5	Addition of CNTF does not lead to an Increase in O4+ Oligodendrocytes	92
Figure 4.6	anti-CNTF Slightly Increases the Number of Activated Microglia	94
Figure 4.7	Addition of CNTF does not Increase Neurite Diameter	95
Figure 4.8	Addition of CNTF and Astrocyte Reactivity.	97
Figure 4.9	Addition of CNTF and Nestin Reactivity	98

Chapter 5

Figure 5.1	An Illustration of CNTF Binding and Signalling	104
Figure 5.2	CNTFR α can be Soluble or Membrane Bound	105
Figure 5.3	Receptor Complexes of the IL-6 Cytokines	106
Figure 5.4	Neutralising CNTF leads to an Increase in Myelination	109
Figure 5.5	Myelination is only increased at 4 μ g/ml	110
Figure 5.6	Antibody Treatment Leads to a Slight Reduction in CNTF in Media from Cultures	112
Figure 5.7	Addition of CNTF and anti-CNTF at Different Time Points Suggests that there may be Two Different Mechanisms for Their actions	113
Figure 5.8	Addition of anti-CNTF does not lead to an Increase in O4+ Oligodendrocytes	115

Figure 5.9	Addition of anti-CNTF does not lead to the Proliferation of O4+ Cells	116
Figure 5.10	anti-CNTF does not Increase the Number of Activated Microglia	118
Figure 5.11	anti-LIF addition leads to an Increase in Myelination	119
Figure 5.12	Illustration of the Possible Biphasic Effect of CNTF	123
Figure 5.13	Illustration of the Possible Competition between IL-6 Cytokines	124

Chapter 6

Figure 6.1	Myelination was Reduced on Astrocytes plated on TnC	129
Figure 6.2	Cellular Characteristics of Astrocytes on PLL and TnC are Similar	131
Figure 6.3	Astrocyte plated on PLL Exhibit an ‘Activated’ Phenotype whilst those on TnC Exhibit a ‘Quiescent’ Phenotype	133
Figure 6.4	Confluency is achieved when Astrocytes are plated on PLL and TnC	134
Figure 6.5	Plating Astrocytes on a TnC Substrate Does Not Affect Neurite Extension or Expression of TnC on Astrocytic Surface	135
Figure 6.6	Myelinating Cultures Conditioned with Astrocytes Pre-treated with CNTF Increased Myelination and this effect was Dominant to the Reduction in Myelination by Quiescent Astrocytes.	137

Chapter 7

Figure 7.1	Schematic Diagram Representing the Experimental Plan and Step Wise Process of a Microarray Study	146
Figure 7.2	Venn diagram Representing Transcript Distribution over time in PLL-astrocytes with and without CNTF Treatment.	147
Figure 7.3	Venn diagram Representing Transcript Distribution between PLL-astrocytes Untreated and Treated with CNTF after 4 hours and 24 hours	153
Figure 7.4	Venn diagram Representing Transcript Distribution between TnC-astrocytes compared to PLL-astrocytes untreated and treated with CNTF after 4 hours	158
Figure 7.5	Venn diagram Representing Transcript Distribution between TnC-astrocytes at 4 hours compared to PLL-astrocytes untreated and treated with CNTF at 24 hours	161
Figure 7.6	Validation of CXCL10 in TnC-Astrocytes	166

Figure 7.7	CXCL10 Neutralising Antibodies Increase Myelination in TnC-Astrocytes	169
Figure 7.8	CXCL10 Neutralising Antibodies Increase Myelination in TnC-Astrocytes with No Effect on Neurite Density	170
Figure 7.9	The Addition of CXCL10 to Myelinating Cultures on PLL-Astrocytes Resulted in a Decrease in Myelination	171
Figure 7.10	The Addition of CXCL10 to Myelinating Cultures on TnC-Astrocytes does not Affect Myelination	172
Figure 7.11	CXCL10 is Slightly Reduced in Myelinating Cultures plated on TnC-Astrocytes Treated with CNTF as Measured by qRT-PCR	173

Chapter 8

Figure 8.1	NF- κ B Activation and its effects on Oligodendrocyte Precursor Cells	189
------------	--	-----

List of Tables

Chapter 2

Table 2.1	Primary Antibody List	45
Table 2.2	Secondary Antibody List	45

Chapter 7

Table 7.1	Genes Identified by Microarray Expression Profiling between PLL-Astrocytes at 4 and 24 hours (Section A of Figure 7.2)	148
Table 7.2	Genes Identified by Microarray Expression Profiling between PLL-Astrocytes Treated with CNTF at 4 and 24 hours (Section B of Figure 7.2)	149
Table 7.3	Genes Identified by Microarray Expression Profiling between PLL-Astrocytes Untreated and Treated with CNTF after 4 and 24 hours (Section AB of Figure 7.2)	151
Table 7.4	Genes Identified by Microarray Expression Profiling between PLL-Astrocytes Untreated and Treated with CNTF after 24 hours (Figure 7.3)	154
Table 7.5	Genes identified by Microarray Expression Profiling between TnC-Astrocytes and PLL-Astrocytes untreated (A) and treated with CNTF (B) after 4 hours (Figure 7.4, A and B).	159
Table 7.6	Genes identified by Microarray Expression Profiling between TnC-Astrocytes and both PLL-Astrocytes untreated and treated with CNTF at 4 hours (Figure 7.4, Section AB).	160
Table 7.7	Genes identified by Microarray Expression Profiling between TnC-Astrocytes at 4 hours and PLL-Astrocytes at 24 hours (Figure 7.5, Section A).	162
Table 7.8	Genes Identified by Microarray Expression Profiling between TnC-Astrocytes after 4 hours and PLL-Astrocytes Treated with CNTF after 24 hours (Figure 7.5, Section B)	163
Table 7.9	Genes Identified by Microarray Expression Profiling between TnC-Astrocytes after 4 hours and PLL-Astrocytes Untreated and Treated with CNTF after 24 hours (Figure 7.5, Section AB)	164

List of Abbreviations

-/-	knockout
3D	three dimensional
A β	Amyloid beta
ACM	astrocyte conditioned medium
AQ4	aquaporin-4
ATP	adenosine triphosphate
BBB	blood brain barrier
BDNF	brain derived neurotrophic factor
BMP	bone morphogenetic protein
BrdU	5-bromo-2'-deoxyuridine
Caspr	contactin associated protein
cDNA	cellular deoxyribonucleic acid
CNP	2',3'-cyclic nucleotide 3'-phosphohydrolase
CNS	central nervous system
CNTF	ciliary neurotrophic factor
CNTFR α	CNTF R alpha
CO ₂	carbon dioxide
CSF	cerebrospinal fluid
CSPGs	chondroitin sulphate proteoglycans
CTGF	connective tissue growth factor
Cx-	Connexin
CXCL10	C-X-C motif chemokine 10
DAPI	4'-6-diamidino-2-phenylindole
DIV	days <i>in vitro</i>
DMEM	Dulbecco's Modified Eagle Medium
dNTP	Deoxyribonucleotide triphosphate
DRG	dorsal root ganglion
E	embryonic day
EAE	experimental autoimmune encephalitis
ECM	extracellular matrix
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
E-NCAM	embryonic form of polysialic acid containing N-CAM
FBS	foetal bovine serum
FCS	foetal calf serum
FDR	false discovery rate
FGF	fibroblast growth factor
FGFR	fibroblast growth factor receptor
GalC	galactocerebroside
GDF15	growth differentiation factor 15
GFAP	glial fibrillary acidic protein
GPI	glycosylphosphatidylinositol
IGF	insulin-like growth factors
IL-	Interleukin-
IP ₃	Inositol trisphosphate
Kv	voltage-gated potassium channels
KO	knockout
L-15	Leibovitz medium
LIF	leukaemia inhibitory factor
LIFR β	leukaemia inhibitory factor receptor beta
LPS	Lipopolysaccharides

μM	micromoles
MAG	myelin associated glycoprotein
MBP	myelin basic protein
min	minute(s)
MOG	Myelin oligodendrocyte glycoprotein
mRNA	mitochondrial ribonucleic acid
MS	multiple sclerosis
Nav	voltage-gated sodium channels
N-CAM	neural cell adhesion molecule
Nf155	155kDa isoform of neurofascin
Nf186	186kDa isoform of neurofascin
Nrg	neuregulin
NSC	neural stem cell
OEC	olfactory ensheathing cells
OPCs	oligodendrocyte progenitor cells
OSM	oncostatin M
p75NTR	low affinity neurotrophin receptor p75
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PDGF	platelet-derived growth factor
PLL	poly-L-lysine
PLP	proteolipid protein
PNS	peripheral nervous system
PTN	pleitrophin
qRT-PCR	quantitive real time polymerase chain reaction
rpm	revolutions per minute
RT	room temperature
T12.5	12.5 cm ³ tissue culture flask
T25	25 cm ³ tissue culture flask
TGF-β1	Transforming growth factor beta
THBS4	thrombospondin-4
TnC	Tenascin-C
TNFα	Tumour necrosis factor-alpha
TNR	Tenascin-R
WMD	white matter disease

Abstract

Astrocytes are the most abundant cell within the central nervous system (CNS) and yet despite this, the true extent of their role in health and disease has not been fully elucidated. In the undamaged CNS, they are termed quiescent, where they maintain homeostasis. However, after injury or disease astrocytes become reactive where they are described as a physical and molecular barrier to regeneration. Emerging literature has suggested the existence of an additional phenotype of astrocyte, termed the activated astrocyte. These astrocytes are thought to enhance regeneration by creating a more growth-permissive environment for repair. In addition, it has also been reported that astrocytes may play a role in regulating myelination; however, it is unclear how the phenotype of the astrocytes may affect this process. Therefore, this thesis will focus on the variable phenotypic state of astrocytes and subsequently how this relates to their ability to support myelination.

Using an *in vitro* myelinating culture, where dissociated spinal cord cells were plated on a monolayer of astrocytes, myelination can be followed over time. Since it is hypothesised that astrocytes can affect myelination we used two protocols known to affect the reactive status of the astrocyte, i) activate the astrocytes by treating with ciliary neurotrophic factor (CNTF) or ii) induce a quiescent astrocyte state by plating them on Tenascin C (TnC).

It is hypothesised that CNTF changes the activation state of the astrocyte therefore making it more supportive to myelination. The addition of the astrocyte derived factor ciliary neurotrophic factor (CNTF) was shown to enhance myelination. My results demonstrate that CNTF addition does not lead to an increase in oligodendrocyte or microglia cell numbers or an increase in the diameter of the neurites, thus suggesting that this CNTF-induced increase in myelination is mediated via the astrocyte.

Conversely, culturing astrocytes on the extracellular matrix molecule Tenascin-C (TnC), a method to make the astrocytes quiescent (Holley et al., 2005), resulted in a reduction in myelination. Astrocytes cultured on TnC were shown have decreased expression of nestin, which is typically a marker for reactivity. A microarray gene study comparing gene expression of the various astrocyte phenotypes identified CXCL10 to be upregulated in astrocytes on TnC. Furthermore, the addition of CXCL10 into the myelination cultures resulted in a decrease in myelination. Conversely, the addition of anti-CXCL10 to myelinating cultures on quiescent astrocytes increased myelination.

Taken together, these data indicate that the astrocyte phenotype has considerable influence on myelination; where activated astrocytes support myelination whilst quiescent astrocytes do not. The identification of factors which may modify astrocyte phenotypes could lead to potential therapeutic strategies for CNS pathologies.

Author's Declaration

I declare that, except where explicit reference is made to the contribution of others, that this dissertation is the result of my own work and has not been submitted for any other degree at the University of Glasgow or any other institution.

Signature _____

Printed name _____